Lymphomas


Share

Program Content

Activities

  • ASH 2024 Lymphomas
    ASH 2024 Conference to Clinic: Lymphomas
    Conference Coverage
    Slideset
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 14, 2025

    Expires: July 13, 2025

Activities

AZD0486 for RR FL
AZD0486, a CD19 x CD3 Bispecific Antibody, for Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

MITHIC FL1 Mosunetuzumab
MITHIC-FL1: Phase II Study of Single-Agent Mosunetuzumab in Patients With Newly Diagnosed Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2024

Expires: December 08, 2025

BRUIN CLL-321
BRUIN CLL-321: Phase III Trial of Pirtobrutinib vs Idelalisib + Rituximab or Bendamustine + Rituximab in Covalent BTK Inhibitor–Pretreated CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2024

Expires: December 10, 2025

ALTAMIRA
ALTAMIRA: Phase II Trial of Acalabrutinib + Rituximab as First-line Treatment for Mantle Cell Lymphoma in Patients Aged ≥60 Yr
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

inMIND
inMIND: A Phase III Study of Tafasitamab, an Anti-CD19 Antibody, Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

ECOG ACRIN EA4151
ECOG-ACRIN EA4151: Phase III Trial of Autologous Hematopoietic Cell Transplantation in MRD-Negative Patients With Mantle Cell Lymphoma in First Complete Remission
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

AMPLIFY
AMPLIFY: First-line Fixed-Duration Acalabrutinib + Venetoclax ± Obinutuzumab vs CIT in CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2024

Expires: December 11, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

This educational activity is supported by independent medical educational grants from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Incyte Corporation, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Bristol Myers Squibb

GlaxoSmithKline

Incyte Corporation

Lilly

Novartis Pharmaceuticals Corporation